产品新闻

重组抗小鼠靶点抗体、重组抗人靶点抗体、同型对照抗体、标签抗体等抗体产品相关的产品新闻。

Syd Labs体内实验级重组抗小鼠PD-(L)1 / VEGF双特异性抗体

Syd Labs 体内实验级重组抗小鼠PD-(L)1 / VEGF双特异性抗体

Syd Labs 体内实验级重组抗小鼠PD-(L)1 / VEGF双特异性抗体(抗小鼠PD-1/VEGF双抗、抗小鼠PD-L1/VEGF双抗)是用哺乳动物细胞生产的重组抗体，多用于动物肿瘤模型研究，可与对应分型的双特异性同型对照抗体配套使用。如要订购，欢迎咨询！

2025年11月7日产品新闻, 新闻, 资讯, , , , , , , Read more...
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.
Figure 4 CTLA-4 blockade is less effective in aged mice. CT26 tumor cells were subcutaneously implanted on the flank of female BALB/c mice either at 6-8 weeks old (young) or at 60-72 weeks old (aged). (A, B) The mice were treated with anti-CTLA-4 antibody IP at 10 mg/kg twice weekly starting 7 days after tumor cell implantation for a total of 6 doses. (A) Kaplan-Meier curves showing time-to-welfare endpoint. 38 mice per group. (B) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-CTLA-4 antibody treatment compared to age-matched untreated mice. 38 mice per group. (C, D) The mice were treated IP at 10 mg/kg twice weekly for a total of 6 doses with a combination of anti-PD-L1 antibody (starting 4 days after tumor cell implantation) and anti-CTLA-4 antibody (starting 7 days after tumor cell implantation). (C) Kaplan-Meier curves showing time-to-welfare endpoint. 37-38 mice per group. (D) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-PD-L1 and anti-CTLA-4 antibodies compared to age-matched untreated mice. 37-38 mice per group. The results in panels (A, B) include data from 3 experiments and the results in panels (C, D) include data from 4 experiments. ns, non-significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.
Figure 1 The effect of anti-PD-1 and anti-CTLA-4 antibodies on the tumor growth in B16-F10-bearing mice. (A) A schematic diagram illustrating the chronological events of experiments (n=8). (B) Tumor growth kinetics in anti-PD-1 day 1-4-7, anti-PD-1 day 11-14-17 or anti-CTLA-4 day 1-4-7 treated B16-F10-bearing mice, compared with vehicle (n=2). Data are mean ± SEM. (C,D,E,F,G,H) The correlation of tumor size and tumor-infiltrating and splenic immune cell population infiltrating CD45+CD3+ (C), CD45+CD3+CD8+ T cells (D), CD45+CD3+CD4+ T cells (E) and CD45+CD11b+ myeloid cells (F), splenic CD45+CD3+CD8+ (G) and CD45+CD3+CD4+ T cells (H). VE, vehicle; PD1, anti-PD-1 day 1-4-7; PD11, anti-PD-1 day 11-14-17; CT, anti-CTLA-4 day 1-4-7; PD-1, programmed cell death-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.

9D9抗体在不同小鼠肿瘤模型中怎么给药？

9D9抗体（抗小鼠CTLA-4单抗）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在不同小鼠肿瘤模型中的给药方案如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , , , , , , , , , , , Read more...
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.

抗小鼠CTLA-4抗体(9D9)在Hepa1-6肝细胞癌模型中怎么给药？

抗小鼠CTLA-4抗体（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在Hepa1-6肝细胞癌模型中的给药方案如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , Read more...
a Group mean TV from treatment initiation on Day 10 through end of study on Day 34. n = 10 mice/group. All animals survived through Day 34 with exception of one animal in untreated group which exited study on Day 32. SPD suspensions (40 mg/mL) and vehicle were dosed IT on Days 10, 14, 18, and 22 (red triangles). Anti-mCTLA-4 (10 mg/kg) was dosed IP on Days 10, 13, 17, and 20 (black diamonds). The combination group received both SPD and anti-mCTLA-4 on the same schedules as the monotreatments. b Group mean percent change in body weight from treatment initiation on Day 10 through end of study on Day 34. Error bars =  ± SEM. Significance reported for Day 34 versus untreated/vehicle controls; ns not significant, *p 

抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型中怎么给药？

抗小鼠CTLA-4单抗（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在4T1乳腺癌模型中的给药方案如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , Read more...

9D9抗体在胃肠道间质瘤模型中怎么给药？

9D9抗体（抗小鼠CTLA-4单抗）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在胃肠道间质瘤模型中的给药方案如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , Read more...

抗小鼠CTLA-4抗体(9D9)在ID8卵巢癌模型中怎么给药？

抗小鼠CTLA-4抗体（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在ID8卵巢癌模型中的给药方案如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , Read more...
Figure 1.Eradication of established tumors by mAb combinations. When s.c. tumors had approximately 25 mm2 surface area, they were injected with indicated single mAbs or mAb combinations for 6 times as shown by arrows. A, survival curves for mice with s.c. SW1 melanoma (left), B16 melanoma (middle), or TC1 lung carcinoma (right). B, tumor growth curves for individual mice with s.c. SW1 melanoma (top), B16 melanoma (middle), or TC1 lung carcinoma (bottom). n = 5 for each group; *, P < 0.05; **, P < 0.01; ***, P < 0.001. Similar results were obtained in at least three independent experiments, summarized in Table 1.

抗小鼠CTLA-4单抗(9D9)在TC1肺癌模型中怎么给药？

抗小鼠CTLA-4单抗（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在TC1肺癌模型中的给药方案如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , Read more...

9D9抗体在SW1黑色素瘤模型中怎么给药？

9D9抗体（抗小鼠CTLA-4单抗）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在SW1黑色素瘤模型中的给药方案如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , Read more...